416 related articles for article (PubMed ID: 25516485)
1. A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Koul S; Andell P; Martinsson A; Smith JG; Scherstén F; Harnek J; Götberg M; Norström E; Björnsson S; Erlinge D
BMC Cardiovasc Disord; 2014 Dec; 14():189. PubMed ID: 25516485
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Wouter Jukema J; Collet JP; De Luca L
Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
[TBL] [Abstract][Full Text] [Related]
4. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
Nührenberg TG; Trenk D; Leggewie S; Ristau I; Amann M; Stratz C; Hochholzer W; Valina CM; Neumann FJ
Platelets; 2013; 24(7):549-53. PubMed ID: 23216528
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
[TBL] [Abstract][Full Text] [Related]
9. Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction.
Park KH; Jeong MH; Lee KH; Sim DS; Yoon HJ; Yoon NS; Kim KH; Park HW; Hong YJ; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
J Cardiol; 2014 Feb; 63(2):99-105. PubMed ID: 24012432
[TBL] [Abstract][Full Text] [Related]
10. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
13. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
[TBL] [Abstract][Full Text] [Related]
14. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
15. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
[TBL] [Abstract][Full Text] [Related]
16. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel.
Koshy A; Balasubramaniam K; Noman A; Zaman AG
Cardiovasc Ther; 2014 Feb; 32(1):1-6. PubMed ID: 24428852
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
Alexopoulos D; Xanthopoulou I; Plakomyti TE; Theodoropoulos KC; Mavronasiou E; Damelou A; Hahalis G; Davlouros P
Am Heart J; 2013 Jan; 165(1):73-9. PubMed ID: 23237136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
